Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update

Rhea-AI Summary

Aethlon Medical, Inc. (AEMD) reported financial results for Q2 2022, with a net loss of approximately $3.8 million, a significant increase from $2.0 million in Q2 2021. Operating expenses rose to $3.67 million, up 71% year-over-year. The company has terminated its U.S. COVID-19 trial and head and neck cancer safety trial due to low patient enrollment, reallocating funds to advance the Hemopurifier in oncology research. As of September 30, 2022, Aethlon had a cash balance of $19.6 million and plans to launch a new oncology trial while engaging a new CRO in the U.S. and Australia.

Positive

• Allocation of saved funds (up to $5 million) to advance Hemopurifier in oncology.
• Launch of a wholly owned subsidiary in Australia to focus on oncology.

Negative

• Increased net loss to $3.8 million from $2.0 million year-over-year.
• Operating expenses increased by 71%, rising from $2.14 million to $3.67 million.
• Termination of U.S. COVID trial and head and neck cancer safety trial due to low enrollment.

SAN DIEGO, Nov. 14, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments. 

Company Updates

Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood. This action has potential applications in cancer, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases, including removal of COVID-19 virus, associated variants, and related exosomes.

• Due to a scarcity of COVID patients in intensive care units eligible for enrollment into our U.S. COVID trial, we recently decided to terminate the agreement with our contract research organization (CRO). As a result, while our Investigational Device Exemption (IDE) related to severe viral infections remains open, we are discontinuing U.S. COVID clinical trial activity. We expect this decision to save the company up to $5 million over the next twelve months, which we intend to allocate towards advancing the study of our Hemopurifier in oncology.
• Due to lack of patient enrollment by the University of Pittsburgh Medical Center (UPMC) in our head and neck cancer safety trial, we and UPMC have terminated this study. We are planning a new clinical trial in oncology that will potentially include more tumor types, enabling us to build our safety database in oncology and provide data to help direct the development of our Hemopurifier as a treatment option in oncology. We are in the latter stages of selecting a new CRO to supervise this new oncology study.
• In October 2022, we launched a wholly owned subsidiary in Australia, formed to conduct clinical research, seek regulatory approval, and commercialize our Hemopurifier in that country. The subsidiary will initially focus on the oncology market in Australia. Once selected, it is likely that our new CRO will oversee planned oncology studies in both the U.S. and Australia.
• Our COVID-19 trial site in India remains open with the goal of enrolling additional COVID-19 patients. We are considering opening an oncology trial in India as well.
• The addition of a second supplier for Galanthus nivalis agglutinin (GNA), used in the resin of our Hemopurifier, is delayed in the U.S., pending approval by the U.S. Food and Drug Administration (FDA) of the supplement to our IDE required to enact this manufacturing change. In our opinion, the FDA has mandated unexpectedly high testing requirements for a product in the safety and feasibility stage of development. The additional data requested by FDA may take us several months to obtain. We are escalating our concerns with the FDA decision by engaging the FDA's ombudsman. However, there can be no assurance that this escalation will accelerate our development timelines.
• Regulatory authorities in India have accepted this manufacturing change and, as a result, we will ship new cartridges to the site in India for use in our clinical trials there.
• We have engaged a major testing lab, Battelle (Columbus, OH), to perform an in vitro study to examine the binding of the current Monkeypox strain to a miniature version of our Hemopurifier.

Financial Results for the Second Quarter Ended September 30, 2022

As of September 30, 2022, Aethlon Medical had a cash balance of approximately $19.6 million.

Consolidated operating expenses for the three months ended September 30, 2022 were approximately $3.67 million, compared to $2.14 million for the three months ended September 30, 2021. This increase of $1.53 million, or 71%, in the 2022 period was due to increases in our general and administrative expenses of $863,000, in our professional fees of $354,000 and in our payroll and related expenses of $307,000.

The $863,000 increase in our general and administrative expenses was primarily due to the combination of a $384,000 increase in our clinical trial expenses, a $258,000 increase in supplies, primarily for manufacturing Hemopurifiers, a $140,000 increase in subcontract expenses related to our government contracts, a $50,000 increase in our rent expense and a $32,000 increase in our insurance expense.

The $354,000 increase in our professional fees was primarily due to the combination of a $152,000 increase in our contract labor expense associated with product development and analytical services, a $136,000 increase in our legal fees and a $61,000 increase in our investor relations expenses, primarily related to solicitation expenses associated with our 2022 annual meeting of stockholders.

The $307,000 increase in our payroll and related expenses was due to an increase in our stock-based compensation expense of $112,000. Our cash-based compensation expense increased by $195,000 due to our increased headcount.

In September 2022, the Board of Directors of Exosome Sciences, Inc. (ESI) and Aethlon, as the majority stockholder of ESI, approved the dissolution of ESI. As a result of this dissolution, we recorded a non-cash charge of $142,121 as other expense in the three months ended September 30, 2022.

Aethlon did not record any revenue related to our government contract with the NIH in the three months ended September 30, 2022, compared to approximately $132,000 in the three months ended September 30, 2021. As of September 30, 2022, the Company had approximately $574,000 of deferred revenue related to those contracts as a result of not achieving certain milestones in those contracts. The NIH award contract ended on September 15, 2022 and we presented the required final report to the NCI. Once the NCI completes the close out review of the contract, we expect to recognize as revenue the $574,000 currently recorded as deferred revenue on our September 30, 2022 balance sheet.

As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.

During the six months ended September 30, 2022, the Company raised approximately $8.9 million in net proceeds under our ATM agreement with H.C. Wainwright & Co., pursuant to sales of our common stock.  

The unaudited condensed consolidated balance sheet for September 30, 2022, and the unaudited condensed consolidated statements of operations for the three and six months ended September 30, 2022 and 2021 follow at the end of this release.

Conference Call

The Company will hold a conference call today, Monday, Nov.14, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session.

Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10172901/f4fe08e0d7

Please note that registered participants will receive their dial in number upon registration.

Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE):	1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN:	1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call. 

A replay of the call will be available approximately one hour after the end of the call through December 14, 2022. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 2753791.

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company developing the Hemopurifier, a therapeutic blood filtration system indicated for cancer and infectious diseases. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.

The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. Under an Investigational Device Exemption (IDE) application, the FDA approved a single site, open-label Early Feasibility Study (EFS) to evaluate the Hemopurifier for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. In two case studies of patients treated under Emergency Use (EU), the Hemopurifier demonstrated binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus from the circulation of a human patient.

Additional information can be found at www.AethlonMedical.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to launch its clinical trials in Australia and expand its trials in India, the Company's ability to obtain FDA approval of its new GNA supplier in a timely manner,  the Company's ability to submit to the FDA and have the FDA approve an EUA for the MPXV, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company's ability to raise additional funds, the Company's ability to obtain Emergency Use authorization from the FDA for use of the Hemopurifier to treat patients with the MPXV; the Company's ability expand its clinical trials into other areas of cancer, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2022, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303

 

AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Balance Sheets
ASSETS
			September 30, 2022		March 31, 2022
CURRENT ASSETS
	Cash		$19,604,025		$17,072,419
	Accounts receivable		114,849		127,965
	Prepaid expenses		784,638		956,623
TOTAL CURRENT ASSETS			20,503,512		18,157,007
	Property and equipment, net		1,138,623		441,238
	Right-of-use lease asset		1,282,328		696,698
	Patents, net		1,925		2,200
	Restricted cash		87,506		87,506
	Deposits		33,305		33,305
	TOTAL ASSETS		$23,047,199		$19,417,954
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
	Accounts payable		361,001		499,962
	Due to related parties		177,527		155,742
	Deferred revenue		574,245		344,547
	Lease liability, current portion		247,144		126,905
	Other current liabilities		741,529		696,893
TOTAL CURRENT LIABILITIES			2,101,446		1,824,049
	Lease liability, less current portion		1,077,529		602,505
TOTAL LIABILITIES			3,178,975		2,426,554
COMMITMENTS AND CONTINGENCIES
EQUITY
	Common stock, par value of $0.001, 60,000,000 shares
	authorized; 22,946,232 and 15,419,163 issued and outstanding		22,948		15,421
	Additional-paid in capital		156,887,555		147,446,868
	Accumulated deficit		(137,042,279)		(130,329,181)
TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS			19,868,224		17,133,108
Noncontrolling interests			-		(141,708)
TOTAL STOCKHOLDERS' EQUITY			19,868,224		16,991,400
	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$23,047,199		$19,417,954

 

AETHLON MEDICAL, INC. AND SUBSIDIARY
Consolidated Statements of Operations
For the three and six month periods ended September 30, 2022 and 2021
		Three Months		Three Months		Six Months		Six Months
		Ended 9/30/22		Ended 9/30/21		Ended 9/30/22		Ended 9/30/21
Government contract revenue		$-		$131,966		$-		$263,932
OPERATING COSTS AND EXPENSES
Professional fees		1,003,870		649,460		1,847,899		1,232,929
Payroll and related		1,112,955		805,608		2,142,641		1,822,350
General and administrative		1,548,484		685,702		2,582,505		1,315,895
Total operating expenses		3,665,309		2,140,770		6,573,045		4,371,174
OPERATING LOSS		(3,665,309)		(2,008,804)		(6,573,045)		(4,107,242)
OTHER EXPENSE
Loss on dissolution of subsidiary		142,121		-		142,121		-
NET LOSS		$(3,807,430)		$(2,008,804)		$(6,715,166)		$(4,107,242)
Loss attributable to noncontrolling interests		-		(825)		-		(1,960)
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.		$(3,807,430)		$(2,007,979)		$(6,715,166)		$(4,105,282)
Basic and diluted net loss available to
common stockholders per share		$              (0.18)		$              (0.13)		$          (0.37)		$          (0.29)
Weighted average number of common
shares outstanding		20,744,999		15,386,486		18,130,177		14,114,639

 

View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-second-quarter-financial-results-and-provides-corporate-update-301677433.html

SOURCE Aethlon Medical, Inc.

FAQ

What were Aethlon Medical's Q2 2022 financial results?

Aethlon Medical reported a net loss of approximately $3.8 million and operating expenses of $3.67 million for Q2 2022.

How much cash did Aethlon Medical have as of September 30, 2022?

Aethlon Medical had a cash balance of approximately $19.6 million as of September 30, 2022.

What trials did Aethlon Medical terminate recently?

Aethlon Medical terminated its U.S. COVID clinical trial and head and neck cancer safety trial due to low patient enrollment.

What future plans does Aethlon Medical have for clinical trials?

Aethlon plans to launch a new oncology trial and has formed a subsidiary in Australia to focus on cancer treatments.

What is the significance of Aethlon Medical's cash reserve?

The cash reserve of $19.6 million allows Aethlon Medical to fund ongoing research and clinical development.